Immunological co-ordination between gut and lungs in SARS-CoV-2 infection

Ahlawat, Shruti; Asha, Asha; Sharma, Krishna Kant

doi:10.1016/j.virusres.2020.198103

Cited by 113 publications

(107 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The affinity of SARS-CoV-2 to the respiratory epithelium and gastrointestinal epithelium is because of the receptor angiotensin-converting enzyme-2[ACE-2] in the brush border of gut enterocytes and lungs alveolar epithelial type II cells ( Hoffmann et al, 2020 ). The presence of viral RNA of SARS-CoV-2 in faecal samples of COVID-19 patients ( Ahlawat et al, 2020 ) confirm their gut inhabitation. The co-infection in the gut impairs the physiology of the gut and eliminates “Good “bacteria making an imbalance between good and bad bacteria (dysbiosis) ( Trottein and Sokol, 2020 , Lin et al, 2020 ).…”

Section: Probiotic Role In Sars-cov-2 Infectionmentioning

confidence: 80%

Probiotic lactobacilli: Can be a remediating supplement for pandemic COVID-19. A review

Al-Ansari

Sahlah

AlHumaid

et al. 2021

Journal of King Saud University - Science

View full text Add to dashboard Cite

Section: Probiotic Role In Sars-cov-2 Infectionmentioning

confidence: 80%

Probiotic lactobacilli: Can be a remediating supplement for pandemic COVID-19. A review

Al-Ansari

Sahlah

AlHumaid

et al. 2021

Journal of King Saud University - Science

View full text Add to dashboard Cite

“…After SARS-CoV-2 invaded the lung, host immune system was activated and inflammatory cytokines were released. Pulmonary permeability was increased with the release of inflammatory cytokines, which further led to viral invasion of the gut through the gut-lung axis, and vice versa ( Ahlawat et al, 2020 ). In these processes, the intestinal flora acted as a “bridge”.…”

Section: Coronaviruses and Gastrointestinal Lesionsmentioning

confidence: 99%

Gordian Knot: Gastrointestinal lesions caused by three highly pathogenic coronaviruses from SARS-CoV and MERS-CoV to SARS-CoV-2

Meng

Lou

Yang

et al. 2021

European Journal of Pharmacology

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen of 2019 novel coronavirus disease (COVID-19), is currently spreading around the world. The WHO declared on January 31 that the outbreak of SARS-CoV-2 was a public health emergency. SARS-Cov-2 is a member of highly pathogenic coronavirus group that also consists of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Although respiratory tract lesions were regarded as main manifestation of SARS-Cov-2 infection, gastrointestinal lesions were also reported. Similarly, patients with SARS-CoV and MERS-CoV were also observed. Common gastrointestinal symptoms of patients mainly included diarrhea, vomiting and abdominal pain. Gastrointestinal lesions could be used as basis for early diagnosis of patients, and at the same time, controlling gastrointestinal lesions better facilitated to cut off the route of fecal-oral transmission. Hence, this review summarizes the characteristics and mechanism of gastrointestinal lesions caused by three highly pathogenic human coronavirus infections including SARS-CoV, MERS-CoV, as well as SARS-CoV-2. Furthermore, it is expected to gain experience from gastrointestinal lesions caused by SARS-CoV and MERS-CoV infections in order to be able to better relieve SARS-CoV-2 epidemic. Targetin gut microbiota to regulate the process of SARS-CoV-2 infection should be a concern. Especially, the application of nanotechnology may provide help for further controlling COVID-19.

show abstract

“…In addition, it has been demonstrated that ACE2 is also abundantly expressed in gastrointestinal epithelial cells ( 56 , 57 ). Therefore, host cell internalization of SARS-CoV-2 may be identified in the gastrointestinal tract, and can lead to active infection and replication ( 13 ).…”

Section: Two-stage Interaction With Receptors On Host Cellsmentioning

confidence: 99%

Lactoferrin for the treatment of COVID‑19 (Review)

Wang

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) outbreak was caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical outcomes of elderly individuals and those with underlying diseases affected by COVID-19 are serious, and may result in acute respiratory distress syndrome (ARDS) and even mortality. Currently, the clinical treatments for COVID-19 mostly involve symptom alleviation measures and non-specific broad spectrum antiviral drugs, as highly effective antiviral drugs and vaccines are not yet available. Lactoferrin (LF) is a safe iron-binding glycoprotein that is present in the milk of the majority of mammals and exhibits broad-spectrum antiviral activity, including against coronaviruses. In addition, LF also exhibits anti-inflammatory, anti-infective and immune-regulating properties, which are in line with the treatment requirements for SARS-CoV-2 infection. Therefore, the use of LF may be of value in the prevention and/or management of COVID-19. The aim of the present review was to summarize the previous reports on the antiviral properties of LF and compare these with the characteristics of SARS-CoV-2 infection, in order to determine whether LF could be used to assist in the prevention of COVID-19 and to investigate the possible underlying mechanisms governing its mode of action.

show abstract

Immunological co-ordination between gut and lungs in SARS-CoV-2 infection

Cited by 113 publications

References 80 publications

Probiotic lactobacilli: Can be a remediating supplement for pandemic COVID-19. A review

Probiotic lactobacilli: Can be a remediating supplement for pandemic COVID-19. A review

Gordian Knot: Gastrointestinal lesions caused by three highly pathogenic coronaviruses from SARS-CoV and MERS-CoV to SARS-CoV-2

Lactoferrin for the treatment of COVID‑19 (Review)

Contact Info

Product

Resources

About